The trial of RGN-259 (a Thymosin Beta 4-based preservative-free eye drop) is based on data secured from a 72-patient, double-masked, placebo-controlled trial sponsored by RegeneRx and conducted by
Daklinza is a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), while Sunvepra is a NS3/4A protease inhibitor. Currently there are no treatment options for this disease in
GSK noted that trametinib has not showed clinical activity in patients who have progressed on a prior BRAF inhibitor therapy. The EU approval is based on results from
The deal focuses on endometriosis and uterine fibroids with the goal of discovering and developing new treatment options for these diseases. Bayer HealthCare member of the executive committee
The company said that prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these
The CHMP concluded that the benefits of Seasonique outweigh its risks clearing the way for the drug’s approval by local health authorities of the European Union (EU) Member
Investigator Peter Humphrey and his wife Yu Yingzeng were arrested by Chinese police in July 2013 following work they did for GSK. GSK hired Humphrey’s Chinese corporate investigations
Alectinib’s approval was based on data from a Japanese Phase I/II clinical trial (AF-001JP) for people whose tumours were advanced, recurrent or could not be removed completely through
The marketing authorisation is for a new indication for the use of Arzerra (ofatumumab) in combination with chlorambucil or bendamustine to treat patients with chronic lymphocytic leukaemia (CLL)
The completed acquisition concerns products primarily intended for Asia including Japan, South Korea and Europe excluding some countries. Santen’s payment for the closed transaction totalled about $550m and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.